论文部分内容阅读
Ｇｅｌｇｅｎｅ公司生产的沙利度胺 (ｔｈａｌｉｄｏｍｉｄｅ ,Ｔｈａｌｏｍｉｄ) ,其治疗适应证的潜在性正在大量增加。在圣弗朗西斯科举行的美国临床肿瘤学会上报告了新的Ⅱ期临床资料表明 ,沙利度胺对肾细胞癌和恶性胶质瘤有效 ,该公司在这些适应证阳性结果的基础上正在展开
The potential of thalidomide (Thalomid) produced by Gelgene is increasing substantially in its potential for therapeutic indications. A new phase II clinical data was reported at the American Society of Clinical Oncology in San Francisco, indicating that thalidomide is effective in renal cell carcinoma and glioblastoma, and the company is developing on the basis of positive results of these indications.